Lixte Biotechnology Holdings (DB:8640) - Hisse Senedi Fiyatı, Haberler ve Analizler

8640 Stoklara Genel Bakış

LIXTE Biotechnology Holdings, Inc., a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Daha fazla detay

8640 temel anali̇z
Kar Tanesi Skoru
Değerleme	0/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	0/6
Finansal Sağlık	4/6
Temettüler	0/6

Risk Analizi

Kazançlar son 5 yılda yılda 28.3% oranında azaldı

Anlamlı bir piyasa değeri yok ( €6M )

Geliri 1 milyon ABD dolarından az ( $0 )

Hisse senetleri oldukça likit değildir

+ 2 daha fazla risk

Lixte Biotechnology Holdings, Inc. Rakipler

co.don

XTRA:CNW

€6.5m

bioXXmed

XTRA:T5O

€1.4m

Medigene

XTRA:MDG1

€17.4m

4SC

DB:VSC

€50.2m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Lixte Biotechnology Holdings
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$0.63
52 Haftanın En Yüksek Seviyesi	US$15.00
52 Haftanın En Düşük Seviyesi	US$4.12
Beta	-0.44
11 Aylık Değişim	0%
3 Aylık Değişim	-89.75%
1 Yıllık Değişim	-90.74%
33 Yıllık Değişim	n/a
5 Yıllık Değişim	n/a
Halka arzdan bu yana değişim	-97.99%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	8640	DE Biotechs	DE Pazar
7D	0%	-1.1%	1.1%
1Y	-90.7%	-18.8%	7.2%

Getiri vs. Endüstri: 8640 geçen yıl % -18.8 oranında getiri sağlayan German Biotechs sektörünün gerisinde kaldı.

Getiri vs Piyasa: 8640 geçen yıl % 7.2 oranında getiri sağlayan German Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is 8640's price volatile compared to industry and market?
8640 volatility
8640 Average Weekly Movement	n/a
Biotechs Industry Average Movement	6.6%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.4%

İstikrarlı Hisse Senedi Fiyatı: 8640 hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: 8640 'un son bir yıldaki oynaklık değişimini belirlemek için Yetersiz veri.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2005	4	John Kovach	lixte.com

Lixte Biotechnology Holdings, Inc. Temel Bilgiler Özeti

Lixte Biotechnology Holdings'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
8640 temel i̇stati̇sti̇kler
Piyasa değeri	€5.24m
Kazançlar(TTM)	-€5.70m
Gelir(TTM)	n/a

0.0x

P/S Oranı

-0.9x

F/K Oranı

8640 aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
8640 gelir tablosu (TTM)
Gelir	US$0
Gelir Maliyeti	US$0
Brüt Kâr	US$0
Diğer Giderler	US$6.15m
Kazançlar	-US$6.15m

Son Raporlanan Kazançlar

Jun 30, 2023

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-2.73
Brüt Marj	0.00%
Net Kâr Marjı	0.00%
Borç/Özkaynak Oranı	0%

8640 uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

8640 Stoklara Genel Bakış

Risk Analizi

Lixte Biotechnology Holdings, Inc. Rakipler

XTRA:CNW

€6.5m

XTRA:T5O

€1.4m

XTRA:MDG1

€17.4m

DB:VSC

€50.2m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Lixte Biotechnology Holdings, Inc., Annual General Meeting, Dec 19, 2024

Lixte Biotechnology Holdings Receives an Extension Through February 18, 2025 to Regain Compliance with the Stockholders’ Equity Requirement

First Patient Dosed with Lixte Biotechnology Holdings, Inc.’s LB-100 in New Clinical Trial to Treat Colorectal Cancer, Collaborating with NKI, Supported by Major Pharma Company

Lixte Biotechnology Holdings, Inc. Reports Findings Show LIXTE's Lead Clinical Compound, LB-100, Increases Recognition of Colon Cancer Cells by the Immune System

LIXTE Biotechnology Holdings, Inc. Announces Executive Changes

Lixte Biotechnology Holdings, Inc. Announces Publication of Pre-Clinical Data in the Online Journal

Recent updates

Lixte Biotechnology Holdings, Inc., Annual General Meeting, Dec 19, 2024

Lixte Biotechnology Holdings Receives an Extension Through February 18, 2025 to Regain Compliance with the Stockholders’ Equity Requirement

First Patient Dosed with Lixte Biotechnology Holdings, Inc.’s LB-100 in New Clinical Trial to Treat Colorectal Cancer, Collaborating with NKI, Supported by Major Pharma Company

Lixte Biotechnology Holdings, Inc. Reports Findings Show LIXTE's Lead Clinical Compound, LB-100, Increases Recognition of Colon Cancer Cells by the Immune System

LIXTE Biotechnology Holdings, Inc. Announces Executive Changes

Lixte Biotechnology Holdings, Inc. Announces Publication of Pre-Clinical Data in the Online Journal

LIXTE Biotechnology Holdings, Inc. Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments

Lixte Biotechnology Holdings, Inc., Annual General Meeting, Nov 27, 2023

Lixte Biotechnology Holdings, Inc. Announces Chief Executive Officer Changes

LIXTE Biotechnology Holdings, Inc. Announces Supported Collaborative Trial to Study LIXTE’s First-in-Class PP2A Inhibitor, LB-100, Plus GSK’s Immunotherapy, Dostarlimab, in Clear-Cell Ovarian Cancer

LIXTE Biotechnology Holdings, Inc. Announces the Enrollment of the First Patient in the Phase 1b Portion of the Phase 1b/2 Protocol

LIXTE Biotechnology Announces 1-for-10 Reverse Stock Split to Bring it into Compliance with Nasdaq’s Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market

Lixte Biotechnology Holdings, Inc. Announces Recently Published Independent Research Reveals New Mechanisms

Lixte Biotechnology Holdings, Inc. Promotes Eric Forman to Vice President and Chief Operating Officer

LIXTE Biotechnology Holdings, Inc. Announces Spanish Agency for Medicines and Health Products Authorized Phase 1b/Randomized Phase 2 Study of LB-100

Lixte Biotechnology Holdings, Inc., Annual General Meeting, Oct 07, 2022

Lixte Biotechnology Holdings, Inc. Appoints Bastiaan Van Der Baan as Independent Director

Lixte Biotechnology Holdings, Inc. Appoints Bas Van Der Baan to Its Board of Directors

Lixte Biotechnology Holdings, Inc. Announces Appointment of Professor René Bernards to its Board of Directors

Philip Palmedo Not to Stand for Re-Election as Director of Lixte Biotechnology Holdings, Inc

Lixte Biotechnology’s LB-100 Reported to Convert Immunologically Unresponsive (“Cold”) Tumors to Immunologically Responsive (“Hot”) Tumors

Lixte Biotechnology Holdings, Inc. Announces Enrollment Has Resumed in National Cancer Institute’s Trial to Determine Ability of Lixte Compound LB-100 to Enter Recurrent, Malignant Brain Tumors

LixteBiotechnology Holdings, Inc.'s Pre-Clinical Research Demonstrates Inhibition of Protein Phosphatase 2A with LB-100 Combined with the Experimental Drug, Vosoritide

Lixte Biotechnology Holdings, Inc.(NasdaqCM:LIXT) dropped from Russell 3000E Value Index

Lixte Biotechnology and City of Hope Enroll First Patient in Phase 1b Trial of Lead Compound LB-100 for Treatment of Small Cell Lung Cancer

Independent Director has left the company